CHINA LIFE Invests RMB4 Billion in Partnership Focused on Innovative Companies in AI, Integrated Circuits, and Biopharmaceuticals
Partnership Formation: CHINA LIFE, along with Pudong Venture Capital, Guotou Leading, and China Life Infrastructure, is entering a partnership with Chuangzhi Herui and Lingzhiying Shanghai, contributing a total of RMB 5.052 billion, with CHINA LIFE contributing RMB 4 billion.
Investment Focus: The partnership will target investments in technology innovation enterprises, specifically in the sectors of AI, integrated circuits, and biopharmaceuticals.
Trade with 70% Backtested Accuracy
Analyst Views on 02628
About the author
JPM Report: Chinese Insurers Lag Behind Market; PING AN and CHINA LIFE Recommended
Market Performance: After the Lunar New Year holiday, Chinese H-listed insurers have underperformed, with concerns about short-term profit risks and a lack of disclosed premium income data.
JPMorgan's Analysis: JPMorgan's report indicates that major insurers like PING AN and CHINA LIFE are rated as Overweight, with target prices set at $100 and $40, respectively, due to their recovery in life insurance sales.
Profit Forecasts: JPMorgan forecasts significant growth in FY2025 net profits for CHINA LIFE (47%), PING AN (19%), and CPIC (10%) year-over-year.
Short Selling Activity: There is notable short selling activity in both PING AN and CHINA LIFE, with respective ratios of 28.711% and 16.336%, reflecting market skepticism despite their growth prospects.
HSBC Research Projects CHINA LIFE to Face Minimum Loss of RMB7.4B in 4Q25, Optimistic Outlook for PING AN
Profit Alert Regulations: A-share listed companies in China must issue a profit alert if their annual profit growth exceeds 50%, but CHINA LIFE did not issue one despite a 60.5% YoY profit increase, suggesting a potential net loss in Q4 2025.
Market Performance Concerns: HSBC Global Research indicates that CHINA LIFE may underperform the market due to earnings volatility, while investors are more focused on new business value growth.
Comparison with PING AN: Investors favor PING AN's operating profit after tax, which is less affected by market fluctuations, leading to a more positive outlook for PING AN compared to CHINA LIFE.
Target Prices and Ratings: HSBC has set a target price of $84 and a Buy rating for PING AN's H-shares, while CHINA LIFE's H-shares are rated Hold with a target price of $29.
JPM Prefers Materials, Brokerage, Insurance, Consumer Staples, and Robotics Sectors; Sets Year-End MSCI China Index Target at 100
JPMorgan's Upgrade on Chinese Stocks: JPMorgan upgraded its rating of Chinese stocks to Overweight, citing the end of a four-year downward cycle and a favorable entry point for investors, with year-end targets for the MSCI China Index and CSI 300 Index set at 100 and 5,200, respectively.
Shift in Investment Strategy: The firm anticipates a shift in investor focus from short-term trading to long-term appreciation in Chinese stocks, particularly in sectors benefiting from AI, commodities, and consumer staples.
Highlighted Stocks: JPMorgan's investment strategy includes several Chinese stocks rated as Overweight, such as Tencent, Alibaba, and Moutai, with varying short-selling ratios indicating market sentiment.
Market Outlook: The report reflects a more optimistic outlook for leading internet platforms and sectors like robotics and biotechnology, suggesting potential for outperformance in the Chinese market.
Citi's Ratings and Target Prices for Chinese Insurers (Table)
Stock Performance: Several insurance stocks in Hong Kong showed positive movements, with CHINA LIFE increasing by 1.935% and PICC GROUP by 2.744%.
Investment Ratings: Most stocks received a "Buy" rating, including CHINA LIFE, CPIC, and PICC GROUP, while CHINA TAIPING and NCI were rated as "Neutral".
Short Selling Data: Short selling activity varied, with PING AN having the highest short selling amount at $177.33M and a ratio of 22.445%.
Target Price Adjustments: Analysts have adjusted target prices for several stocks, with CHINA LIFE's target raised to HKD40 and PICC P&C's lowered to HKD20.5.
Citi Reports: Upcoming Results Season for Chinese Insurers; China Life Anticipated to Top NBV Growth
Earnings Announcement Period: The earnings announcement period for Hong Kong/China insurers for FY2025 will start on March 19, led by AIA, PRU, and ZA ONLINE.
Growth Expectations: Citi Research anticipates strong growth in new business value for Chinese life insurers, with China Life, Ping An, and CPIC expected to lead with growth rates of 38%, 32%, and 28%, respectively.
Earnings Forecast: The broker predicts solid earnings growth for FY2025, with significant increases expected for China Taiping, China Life, and NCI, among others.
Short Selling Data: The report includes short selling data for various insurers, indicating varying levels of short selling activity and ratios across different companies.
Citi Initiates Positive Catalyst Watch for CHINA LIFE (02628.HK) with Target Price of $40
Stock Performance: CHINA LIFE (02628.HK) saw a stock increase of 1.935%, with short selling amounting to $76.95M and a ratio of 25.746%.
Positive Outlook: Citi Research has opened a positive catalyst watch for CHINA LIFE, anticipating strong FY2025 results and significant new business value growth in 1Q26.
Management Insights: The broker expects management to share favorable updates on 1Q26 new business value growth trends and long-term dividend policies during the FY025 results briefing.
Investment Rating: Citi rated CHINA LIFE as a "Buy" with a target price of $40, citing the company's strong brand, extensive distribution network, and revitalization reform initiatives.
JPM Report: Chinese Insurers Lag Behind Market; PING AN and CHINA LIFE Recommended
Market Performance: After the Lunar New Year holiday, Chinese H-listed insurers have underperformed, with concerns about short-term profit risks and a lack of disclosed premium income data.
JPMorgan's Analysis: JPMorgan's report indicates that major insurers like PING AN and CHINA LIFE are rated as Overweight, with target prices set at $100 and $40, respectively, due to their recovery in life insurance sales.
Profit Forecasts: JPMorgan forecasts significant growth in FY2025 net profits for CHINA LIFE (47%), PING AN (19%), and CPIC (10%) year-over-year.
Short Selling Activity: There is notable short selling activity in both PING AN and CHINA LIFE, with respective ratios of 28.711% and 16.336%, reflecting market skepticism despite their growth prospects.
HSBC Research Projects CHINA LIFE to Face Minimum Loss of RMB7.4B in 4Q25, Optimistic Outlook for PING AN
Profit Alert Regulations: A-share listed companies in China must issue a profit alert if their annual profit growth exceeds 50%, but CHINA LIFE did not issue one despite a 60.5% YoY profit increase, suggesting a potential net loss in Q4 2025.
Market Performance Concerns: HSBC Global Research indicates that CHINA LIFE may underperform the market due to earnings volatility, while investors are more focused on new business value growth.
Comparison with PING AN: Investors favor PING AN's operating profit after tax, which is less affected by market fluctuations, leading to a more positive outlook for PING AN compared to CHINA LIFE.
Target Prices and Ratings: HSBC has set a target price of $84 and a Buy rating for PING AN's H-shares, while CHINA LIFE's H-shares are rated Hold with a target price of $29.
JPM Prefers Materials, Brokerage, Insurance, Consumer Staples, and Robotics Sectors; Sets Year-End MSCI China Index Target at 100
JPMorgan's Upgrade on Chinese Stocks: JPMorgan upgraded its rating of Chinese stocks to Overweight, citing the end of a four-year downward cycle and a favorable entry point for investors, with year-end targets for the MSCI China Index and CSI 300 Index set at 100 and 5,200, respectively.
Shift in Investment Strategy: The firm anticipates a shift in investor focus from short-term trading to long-term appreciation in Chinese stocks, particularly in sectors benefiting from AI, commodities, and consumer staples.
Highlighted Stocks: JPMorgan's investment strategy includes several Chinese stocks rated as Overweight, such as Tencent, Alibaba, and Moutai, with varying short-selling ratios indicating market sentiment.
Market Outlook: The report reflects a more optimistic outlook for leading internet platforms and sectors like robotics and biotechnology, suggesting potential for outperformance in the Chinese market.
Citi's Ratings and Target Prices for Chinese Insurers (Table)
Stock Performance: Several insurance stocks in Hong Kong showed positive movements, with CHINA LIFE increasing by 1.935% and PICC GROUP by 2.744%.
Investment Ratings: Most stocks received a "Buy" rating, including CHINA LIFE, CPIC, and PICC GROUP, while CHINA TAIPING and NCI were rated as "Neutral".
Short Selling Data: Short selling activity varied, with PING AN having the highest short selling amount at $177.33M and a ratio of 22.445%.
Target Price Adjustments: Analysts have adjusted target prices for several stocks, with CHINA LIFE's target raised to HKD40 and PICC P&C's lowered to HKD20.5.
Citi Reports: Upcoming Results Season for Chinese Insurers; China Life Anticipated to Top NBV Growth
Earnings Announcement Period: The earnings announcement period for Hong Kong/China insurers for FY2025 will start on March 19, led by AIA, PRU, and ZA ONLINE.
Growth Expectations: Citi Research anticipates strong growth in new business value for Chinese life insurers, with China Life, Ping An, and CPIC expected to lead with growth rates of 38%, 32%, and 28%, respectively.
Earnings Forecast: The broker predicts solid earnings growth for FY2025, with significant increases expected for China Taiping, China Life, and NCI, among others.
Short Selling Data: The report includes short selling data for various insurers, indicating varying levels of short selling activity and ratios across different companies.
Citi Initiates Positive Catalyst Watch for CHINA LIFE (02628.HK) with Target Price of $40
Stock Performance: CHINA LIFE (02628.HK) saw a stock increase of 1.935%, with short selling amounting to $76.95M and a ratio of 25.746%.
Positive Outlook: Citi Research has opened a positive catalyst watch for CHINA LIFE, anticipating strong FY2025 results and significant new business value growth in 1Q26.
Management Insights: The broker expects management to share favorable updates on 1Q26 new business value growth trends and long-term dividend policies during the FY025 results briefing.
Investment Rating: Citi rated CHINA LIFE as a "Buy" with a target price of $40, citing the company's strong brand, extensive distribution network, and revitalization reform initiatives.
